Abacavir-based Regimen for HIV-infected Children and Adolescents

Indian Pediatr. 2019 Aug 15;56(8):685-686.

Abstract

We studied 48 children receiving abacavir-based HAART regimen, over a period of one-year for side effects and failure rates. None of the children developed hypersensitivity reaction. The CD4 count significantly improved from the time of enrolment till 12 months of therapy while the failure rate was 14.5%.

Publication types

  • Letter
  • Observational Study

MeSH terms

  • Adolescent
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • Child
  • Child, Preschool
  • Dideoxynucleosides / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • HIV Infections / drug therapy*
  • Humans
  • Infant
  • Male
  • Treatment Outcome

Substances

  • Anti-HIV Agents
  • Dideoxynucleosides
  • abacavir